Vivani Medical, Inc. 8-K

What Happened

• Vivani Medical, Inc. (VANI) filed an 8-K reporting that on July 1, 2026 its wholly owned subsidiary Cortigent, Inc. entered into a definitive Agreement and Plan of Merger with ClearOne, Inc. and ClearOne’s merger subsidiary. At the effective time, all issued and outstanding Cortigent equity held by Vivani will convert into 12,500,000 shares of ClearOne common stock (the “Consideration Shares”). The Merger Agreement was attached as Exhibit 2.1 to the filing.
• Vivani also reported a July 7, 2026 press release (filed as Exhibit 99.1) announcing an agreement with Novo Nordisk to evaluate NPM-139, Vivani’s semaglutide implant using its NanoPortal platform for chronic weight management.

Key Details

• Merger date / agreement: Agreement dated July 1, 2026; press release dated July 7, 2026.
• Consideration: Vivani will receive 12,500,000 duly authorized, fully paid ClearOne shares (subject only to standard share adjustments such as splits/dividends).
• Financing requirement: ClearOne must file an S-1 to raise $10.0M–$15.0M by selling 2.5M–5.0M units (each unit = 1 share + 1 warrant). Warrants exercisable at $10/share for six months. The Financing is a condition to closing.
• Governance & approvals: At closing the Combined Company board is expected to have five directors (four designated by Vivani, including the chair). The deal requires customary stockholder approvals; certain ClearOne holders holding ≥50.1% have committed to voting support. Vivani agreed to lock-up the Consideration Shares (50% one-year, 50% two-year).
• Termination / fees: Termination rights include mutual consent, failure to deliver Cortigent stockholder vote, expiration (initial outside date Dec 28, 2026), material breach, or court order. A breakup fee may be payable equal to 125% of direct verifiable third‑party expenses, capped at $250,000.

Why It Matters

• For Vivani investors: Vivani will exchange its Cortigent equity for a fixed block of 12.5M ClearOne shares rather than cash. The value Vivani receives depends on ClearOne’s share price at closing and may be diluted by the required $10M–$15M financing. The Financing and multiple approvals (shareholders, Nasdaq listing actions) are conditions to closing, so the transaction is not guaranteed.
• Corporate control and strategy: If completed, Vivani will have substantial influence on the Combined Company’s board (4 of 5 seats) and potential influence on strategy and operations through those seats and the Consideration Shares.
• Risks highlighted by the filing: the transaction is subject to customary closing conditions and regulatory/Nasdaq requirements; forward‑looking statements and financing risks could affect timing and value. Investors should watch for ClearOne’s S-1 filing, shareholder votes, Nasdaq listing approvals, and subsequent SEC filings for further detail.